{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:45:52Z","timestamp":1780343152811,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","joms.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.joms.2008.11.005","type":"journal-article","created":{"date-parts":[[2009,2,22]],"date-time":"2009-02-22T02:56:40Z","timestamp":1235271400000},"page":"645-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Recurrent Low-Energy Femoral Shaft Fractures and Osteonecrosis of the Jaw in a Case of Multiple Myeloma Treated With Bisphosphonates"],"prefix":"10.1016","volume":"67","author":[{"given":"Jonathan M.","family":"Grasko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel D.","family":"Vasikaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joms.2008.11.005_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJM199602223340810","article-title":"Management of myeloma with bisphosphonates","volume":"334","author":"Bataille","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2008.11.005_bib2","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/1097-0142(19951101)76:9<1559::AID-CNCR2820760910>3.0.CO;2-R","article-title":"Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy","volume":"76","author":"Mariette","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.joms.2008.11.005_bib3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9343(92)90190-M","article-title":"Bone densitometry in patients with multiple myeloma","volume":"93","author":"Mariette","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.joms.2008.11.005_bib4","first-page":"1919","article-title":"Plasma-cell dyscrasia with polyneuropathy","volume":"27","author":"Miralles","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2008.11.005_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/(SICI)1096-8652(199712)56:4<288::AID-AJH16>3.0.CO;2-5","article-title":"Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome)","volume":"56","author":"Lacy","year":"1997","journal-title":"Am J Hematol"},{"key":"10.1016\/j.joms.2008.11.005_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1297-319X(03)00152-0","article-title":"Multiple myeloma presenting with widespread osteosclerotic lesions","volume":"71","author":"Mulleman","year":"2004","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.joms.2008.11.005_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1212\/WNL.33.2.202","article-title":"Osteosclerotic myeloma and peripheral neuropathy","volume":"33","author":"Kelly","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.joms.2008.11.005_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/156800906775471743","article-title":"Anti-cancer therapy: Targeting the mevalonate pathway","volume":"6","author":"Swanson","year":"2006","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.joms.2008.11.005_bib9","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","article-title":"Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin","volume":"13","author":"Tanaka","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.joms.2008.11.005_bib10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2141.1997.1042920.x","article-title":"Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity","volume":"97","author":"Diamond","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.joms.2008.11.005_bib11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","article-title":"Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids","volume":"102","author":"Weinstein","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.joms.2008.11.005_bib12","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1210\/endo.140.11.7135","article-title":"Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro","volume":"140","author":"Gohel","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.joms.2008.11.005_bib13","first-page":"3441","article-title":"Clinical review 83: mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis","volume":"81","author":"Canalis","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.joms.2008.11.005_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0002-9343(98)00081-3","article-title":"Osteoporosis after organ transplantation","volume":"104","author":"Rodino","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.joms.2008.11.005_bib15","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1073\/pnas.79.11.3542","article-title":"Decreased intestinal calcium absorption in vivo and normal brush border membrane vesicle calcium uptake in cortisol-treated chickens: Evidence for dissociation of calcium absorption from brush border vesicle uptake","volume":"79","author":"Shultz","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.joms.2008.11.005_bib16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7326\/0003-4819-104-5-648","article-title":"Reduction of serum testosterone levels during chronic glucocorticoid therapy","volume":"104","author":"MacAdams","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.joms.2008.11.005_bib17","first-page":"168","article-title":"Testosterone concentrations in men on chronic glucocorticosteroid therapy","volume":"31","author":"Fitzgerald","year":"1997","journal-title":"J R Coll Physicians Lond"},{"key":"10.1016\/j.joms.2008.11.005_bib18","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1210\/endo.134.4.8137726","article-title":"Gender-specific, maturation-dependent effects of testosterone on chondrocytes in culture","volume":"134","author":"Schwartz","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.joms.2008.11.005_bib19","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","article-title":"Osteoporosis due to cancer treatment: pathogenesis and management","volume":"18","author":"Pfeilschifter","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2008.11.005_bib20","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","article-title":"POEMS syndrome: Definitions and long-term outcome","volume":"101","author":"Dispenzieri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.joms.2008.11.005_bib21","first-page":"543","article-title":"Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases","volume":"13","author":"Takatsuki","year":"1983","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.joms.2008.11.005_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00005792-198007000-00005","article-title":"Plasma cell neoplasia with peripheral polyneuropathy","volume":"59","author":"Driedger","year":"1980","journal-title":"Medicine"},{"key":"10.1016\/j.joms.2008.11.005_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2008.11.005_bib24","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2008.11.005_bib25","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1056\/NEJMra040952","article-title":"Osteopetrosis","volume":"351","author":"Tolar","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2008.11.005_bib26","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-04-147884","article-title":"Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis","author":"Sarasquete","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.joms.2008.11.005_bib27","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.joms.2008.11.005_bib28","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.joms.2008.11.005_bib29","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.joms.2008.11.005_bib30","first-page":"1121","article-title":"Inhibition of angiogenesis and tumor growth in the brain","volume":"137","author":"Brem","year":"1990","journal-title":"Am J Pathol"},{"key":"10.1016\/j.joms.2008.11.005_bib31","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2008.11.005_bib32","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.1991.9.8.1397","article-title":"Effect of daily etidronate on the osteolysis of multiple myeloma","volume":"9","author":"Belch","year":"1991","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.joms.2008.11.005_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.joms.2008.11.005_bib34","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1172\/JCI200422087","article-title":"An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis","volume":"114","author":"Giraudo","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.joms.2008.11.005_bib35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.11.005_bib36","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2008.11.005_bib37","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.11.005_bib38","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.11.005_bib39","first-page":"1391","article-title":"Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw","volume":"35","author":"Khan","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.joms.2008.11.005_bib40","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate","volume":"358","author":"Lenart","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2008.11.005_bib41","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","article-title":"An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?","volume":"39","author":"Kwek","year":"2008","journal-title":"Injury"},{"key":"10.1016\/j.joms.2008.11.005_bib42","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: A potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.joms.2008.11.005_bib43","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: A population-based sudy","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239108017217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239108017217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:25:16Z","timestamp":1759508716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278239108017217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0278239108017217"],"URL":"https:\/\/doi.org\/10.1016\/j.joms.2008.11.005","relation":{},"ISSN":["0278-2391"],"issn-type":[{"value":"0278-2391","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrent Low-Energy Femoral Shaft Fractures and Osteonecrosis of the Jaw in a Case of Multiple Myeloma Treated With Bisphosphonates","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joms.2008.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}